DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Clinical trials for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for brain cancer: drug combo targets tough tumours
Disease control Recruiting nowThis trial tests two drugs, avutometinib and defactinib, alone or with a third drug (temozolomide), in people with aggressive brain tumours like glioblastoma. The goal is to see if the combination is safe and can shrink tumours or slow their growth. About 182 adults with recurren…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated May 26, 2026 11:49 UTC
-
New hope for kids with aggressive brain tumors: targeted drug combo after radiation
Disease control Recruiting nowThis study tests whether adding two different drug combinations after radiation can help children and young adults with high-grade gliomas (including DIPG) live longer. One group receives ribociclib plus everolimus, and another receives ribociclib plus temozolomide, based on the …
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
Radioactive therapy targets hard-to-treat brain tumors in early trial
Disease control Recruiting nowThis early-phase study tests whether a radioactive drug called 177Lu-PSMA-617 is safe for people with a fast-growing type of brain cancer (IDH wild type glioma). About 20 adults whose tumors express a protein called PSMA will receive the drug after standard treatments. The main g…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC